Search Results 171-180 of 17077 for hla genotype

  1. A Study of the Safety and Effectiveness of QPI-1002 for the Prevention of Delayed Graft Function in Transplant Recipients from Older Kidney Donors who have Died - Mayo Clinic

    ... HLA antibody testing, or by similar methodology, if performed. Has undergone desensitization to remove donor specific anti-HLA antibodies prior to ...

  2. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML - Mayo Clinic

    Have 8/8 allele-level, related or unrelated, HSC donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB1 with a donor who is medically cleared ...

  3. Overview - Genome Analysis Core - Mayo Clinic Research

    The Genome Analysis Core at Mayo Clinic offers DNA and RNA next-generation sequencing (NGS), gene expression and genotyping services for researchers.

  4. Medical Research & Education - Mayo Clinic News Network

    New international practice guidelines for tamoxifen treatment based on CYP2D6 genotype featured image. Cancer. New international practice guidelines for ...

  5. Neurology - Clinical trials - Mayo Clinic

    ... genotype, including understudied APOE2 and APOE4 homozygotes (HMs) at the lowest and highest risk and those APOE4 HMs and heterozygotes (HTs) who remain ...

  6. Department of Immunology - Mayo Clinic Research

    ... human leukocyte antigen (HLA) molecules, and immune cell activation are central to several research projects across the department. Cancer immunology ...

  7. Medical Research & Education - Mayo Clinic News Network

    New international practice guidelines for tamoxifen treatment based on CYP2D6 genotype featured image. Cancer. New international practice guidelines for ...

  8. A Study of Donor-Alloantigen-Reactive Regulatory T Cell Therapy with an Immunosuppression Regimen in Adult Liver Transplantation - Mayo Clinic

    Human leukocyte antigen (HLA)-DR (DR is one of class II antigens) matched to donor at both loci. Subject is < 21 or >70 years of age at the time of ...

  9. Neurology - Clinical trials

    ... genotype, including understudied APOE2 and APOE4 homozygotes (HMs) at the lowest and highest risk and those APOE4 HMs and heterozygotes (HTs) who remain ...

  10. A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) - Mayo Clinic

    * Donor-specific antibody (DSA): Human leukocyte antigen (HLA) Class I and/or II antigen-specific DSA-positive (pre-formed and/or de novo DSA) as determined ...